Literature DB >> 20937595

Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

Emin Oroudjev1, Manu Lopus, Leslie Wilson, Charlene Audette, Carmela Provenzano, Hans Erickson, Yelena Kovtun, Ravi Chari, Mary Ann Jordan.   

Abstract

Maytansine and its analogues (maytansinoids) are potent microtubule-targeted compounds that inhibit proliferation of cells at mitosis. Antibody-maytansinoid conjugates consisting of maytansinoids (DM1 and DM4) attached to tumor-specific antibodies have shown promising clinical results. To determine the mechanism by which the antibody-DM1 conjugates inhibit cell proliferation, we examined the effects of the cleavable anti-EpCAM-SPP-DM1 and uncleavable anti-EpCAM-SMCC-DM1 conjugates on MCF7 human breast tumor cells. We also examined the effects of the free maytansinoids, maytansine and S-methyl DM1 (a version of DM1 that is stable in cell culture medium), for comparison. Both the conjugates and free maytansinoids potently inhibited MCF7 cell proliferation at nanomolar and subnanomolar concentrations, respectively, by arresting the cells in mitotic prometaphase/metaphase. Arrest occurred in concert with the internalization and intracellular processing of both conjugates under conditions that induced abnormal spindle organization and suppressed microtubule dynamic instability. Microtubule depolymerization occurred only at significantly higher drug concentrations. The results indicate that free maytansinoids, antibody-maytansinoid conjugates, and their metabolites exert their potent antimitotic effects through a common mechanism involving suppression of microtubule dynamic instability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937595      PMCID: PMC2976674          DOI: 10.1158/1535-7163.MCT-10-0645

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  43 in total

1.  Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.

Authors:  Kathy Kamath; Mary Ann Jordan
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

Review 2.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

3.  Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells.

Authors:  M K Wolpert-DeFilippes; V H Bono; R L Dion; D G Johns
Journal:  Biochem Pharmacol       Date:  1975-09-15       Impact factor: 5.858

Review 4.  How do microtubule-targeted drugs work? An overview.

Authors:  Mary Ann Jordan; Kathy Kamath
Journal:  Curr Cancer Drug Targets       Date:  2007-12       Impact factor: 3.428

Review 5.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

6.  Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.

Authors:  V K Ngan; K Bellman; B T Hill; L Wilson; M A Jordan
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

7.  Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus.

Authors:  S M Kupchan; Y Komoda; W A Court; G J Thomas; R M Smith; A Karim; C J Gilmore; R C Haltiwanger; R F Bryan
Journal:  J Am Chem Soc       Date:  1972-02-23       Impact factor: 15.419

8.  Antimitotic activity of the potent tumor inhibitor maytansine.

Authors:  S Remillard; L I Rebhun; G A Howie; S M Kupchan
Journal:  Science       Date:  1975-09-19       Impact factor: 47.728

9.  A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.

Authors:  Paul R Helft; Richard L Schilsky; Frank J Hoke; Daphne Williams; Hedy L Kindler; Evie Sprague; Mark DeWitte; Helen K Martino; John Erickson; Lini Pandite; Mark Russo; John M Lambert; Maria Howard; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

10.  Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.

Authors:  Hongsheng Xie; Charlene Audette; Mary Hoffee; John M Lambert; Walter A Blättler
Journal:  J Pharmacol Exp Ther       Date:  2003-11-21       Impact factor: 4.030

View more
  44 in total

1.  High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.

Authors:  Jonathan N Thon; Matthew T Devine; Antonija Jurak Begonja; Jay Tibbitts; Joseph E Italiano
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  Modeling the effects of drug binding on the dynamic instability of microtubules.

Authors:  Peter Hinow; Vahid Rezania; Manu Lopus; Mary Ann Jordan; Jack A Tuszyński
Journal:  Phys Biol       Date:  2011-08-12       Impact factor: 2.583

Review 3.  Optimising the delivery of tubulin targeting agents through antibody conjugation.

Authors:  Gary D Stack; John J Walsh
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

4.  Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.

Authors:  Nichole E LaPointe; Gerardo Morfini; Scott T Brady; Stuart C Feinstein; Leslie Wilson; Mary Ann Jordan
Journal:  Neurotoxicology       Date:  2013-05-24       Impact factor: 4.294

5.  Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.

Authors:  Katharine C Lai; Jutta Deckert; Yulius Y Setiady; Prerak Shah; Lintao Wang; Ravi Chari; John M Lambert
Journal:  Pharm Res       Date:  2015-01-29       Impact factor: 4.200

6.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

7.  The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Authors:  Hernan Carol; Barbara Szymanska; Kathryn Evans; Ingrid Boehm; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2013-02-20       Impact factor: 12.531

Review 8.  Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 9.  Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Authors:  Aiko Nagayama; Leif W Ellisen; Bruce Chabner; Aditya Bardia
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

Review 10.  Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle.

Authors:  Aaron H Colby; Nicholas H Oberlies; Cedric J Pearce; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.